Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women

References

• Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010; 62 6: 1576–1582.
   PubMed Web of Science ®Google Scholar
• Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med. 1999; 341 27: 2068–2074.
   PubMed Web of Science ®Google Scholar
• Bonneville M, Scotet E, Peyrat MA, Saulquin X, Houssaint E. Epstein-Barr virus and rheumatoid arthritis. Rev Rhum Engl Ed. 1998; 65 6: 365–368.
   PubMedGoogle Scholar
• Alspaugh MA, Jensen FC, Rabin H, Tan EM. Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med. 1978; 147 4: 1018–1027.
   PubMed Web of Science ®Google Scholar
• Cooke SP, Rigby SP, Griffiths DJ, Venables PJ. Viral studies in rheumatic disease. Ann Med Interne (Paris). 1998; 149 1: 30–33.
   PubMedGoogle Scholar
• Linde A. 2003. Epstein-Barr virus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. editors. Manual of clinical microbiology. Washington, DC: ASM Press8th ed.1331–1340.
   Google Scholar
• Alspaugh MA, Tan EM. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence. Arthritis Rheum. 1976; 19 4: 711–719.
   PubMedGoogle Scholar
• Baboonian C, Halliday D, Venables PJ, Pawlowski T, Millman G, Maini RN. Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of Epstein-Barr nuclear antigen-1. Rheumatol Int. 1989; 9 3–5: 161–166.
   PubMed Web of Science ®Google Scholar
• Petersen J, Rhodes G, Roudier J, Vaughan JH. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 1990; 33 7: 993–1000.
   PubMedGoogle Scholar
• Rumpold H, Rhodes GH, Bloch PL, Carson DA, Vaughan JH. The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1). J Immunol. 1987; 138 2: 593–599.
   PubMed Web of Science ®Google Scholar
• Kouri T, Petersen J, Rhodes G, Aho K, Palosuo T, Heliovaara M, Isomäki H, von Essen R, Vaughan JH. Antibodies to synthetic peptides from Epstein-Barr nuclear antigen-1 in sera of patients with early rheumatoid arthritis and in preillness sera. J Rheumatol. 1990; 17 11: 1442–1449.
   PubMed Web of Science ®Google Scholar
• Fox R, Sportsman R, Rhodes G, Luka J, Pearson G, Vaughan J. Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen. J Clin Invest. 1986; 77 5: 1539–1547.
   PubMed Web of Science ®Google Scholar
• Roudier J, Petersen J, Rhodes GH, Luka J, Carson DA. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci USA. 1989; 86 13: 5104–5108.
   PubMed Web of Science ®Google Scholar
• Lotz M, Roudier J. Epstein-Barr virus and rheumatoid arthritis: Cellular and molecular aspects. Rheumatol Int. 1989; 9 3–5: 147–152.
   PubMed Web of Science ®Google Scholar
• Birkenfeld P, Haratz N, Klein G, Sulitzeanu D. Cross-reactivity between EBNA 1p107 peptide, collagen and keratin: Implications for the pathogenesis of rheumatoid arthritis. Clin Immunol Immunopathol. 1989; 54:14–25.
   Google Scholar
• Inman RD. Infectious etiology of rheumatoid arthritis. Rheum Dis Clin North Am. 1991; 17 4: 859–870.
   PubMed Web of Science ®Google Scholar
• Carty SM, Snowden N, Silman AJ. Should infection still be considered as the most likely triggering factor for rheumatoid arthritis?. J Rheumatol. 2003; 30 3: 425–429.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Roudier J, Roudier C. Epstein-Barr virus and rheumatoid arthritis. Autoimmun Rev. 2004; 3 5: 362–367.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, Hankinson SE, Hunter DJ. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. J Am Med Assoc. 2001; 286 24: 3083–3088.
   PubMed Web of Science ®Google Scholar
• Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. J Am Med Assoc. 2005; 293 20: 2496–2500.
   PubMed Web of Science ®Google Scholar
• McClain MT, Bruner TL, Dennis GJ, Harley JB, James JA. The temporal relationship between the onset of anti-EBNA-1 and lupus atuoimmunity supports a role for EBV in the development if SLE [abstract]. Arthritis Rheum. 2003; 48 9 suppl: S674.
   Google Scholar
• Heinlen LD, McClain MT, Dennis GJ, Rubertone MV, Harley JB, James JA. The development of antibodies targeting Epstein-Barr virus closely parallels autoimmune progression near the onset of SLE [abstract]. Arthritis Rheum. 2003; 48 9 suppl: S662.
   Google Scholar
• Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. Association of Epstein-Barr virus with systemic lupus erythematosus: Effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum. 2005; 52 4: 1148–1159.
   PubMedGoogle Scholar
• Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med. 2006; 119(6) 503: e1–e9.
   Google Scholar
• Karlson EW, Sanchez-Guerrero J, Wright EA, Lew RA, Daltroy LH, Katz JN, Liang MH. A connective tissue disease screening questionnaire for population studies. Ann Epidemiol. 1995; 5 4: 297–302.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TAJr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31 3: 315–324.
   PubMed Web of Science ®Google Scholar
• Lennette ET, Rymo L, Yadav M, Masucci G, Merk K, Timar L, Klein G. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer. 1993; 29A 11: 1584–1589.
   PubMed Web of Science ®Google Scholar
• Svahn A, Magnusson M, Jagdahl L, Schloss L, Kahlmeter G, Linde A. Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection. J Clin Microbiol. 1997; 35 11: 2728–2732.
   PubMed Web of Science ®Google Scholar
• Bruu AL, Hjetland R, Holter E, Mortensen L, Natas O, Petterson W, Skar AG, Skarpaas T, Tjade T, Asjø B. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol. 2000; 7 3: 451–456.
   PubMedGoogle Scholar
• Gartner BC, Fischinger JM, Roemer K, Mak M, Fleurent B, Mueller-Lantzsch N. Evaluation of a recombinant line blot for diagnosis of Epstein-Barr Virus compared with ELISA, using immunofluorescence as reference method. J Virol Methods. 2001; 93 1–2: 89–96.
   PubMed Web of Science ®Google Scholar
• Sidorchuk A, Lagarde F, Pershagen G, Wickman M, Linde A. Epstein-Barr virus infection is not associated with development of allergy in children. Pediatr Infect Dis J. 2003; 22 7: 642–647.
   PubMed Web of Science ®Google Scholar
• Linde A, Andersson J, Lundgren G, Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol. 1987; 21 2: 109–121.
   PubMed Web of Science ®Google Scholar
• Nordstrom M, Hardell L, Linde A, Schloss L, Nasman A. Elevated antibody levels to Epstein-Barr virus antigens in patients with hairy cell leukemia compared to controls in relation to exposure to pesticides, organic solvents, animals, and exhausts. Oncol Res. 1999; 11 11–12: 539–544.
   PubMed Web of Science ®Google Scholar
• Nordstrom M, Hardell L, Lindstrom G, Wingfors H, Hardell K, Linde A. Concentrations of organochlorines related to titers to Epstein-Barr virus early antigen IgG as risk factors for hairy cell leukemia. Environ Health Perspect. 2000; 108 5: 441–445.
   PubMed Web of Science ®Google Scholar
• Hardell E, Eriksson M, Lindstrom G, Van Bavel B, Linde A, Carlberg M, Liljegren G. Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma. Leuk Lymphoma. 2001; 42 4: 619–629.
   PubMed Web of Science ®Google Scholar
• Akre O, Lipworth L, Tretli S, Linde A, Engstrand L, Adami HO, Melbye M, Andersen A, Ekbom A. Epstein-Barr virus and cytomegalovirus in relation to testicular-cancer risk: A nested case-control study. Int J Cancer. 1999; 82 1: 1–5.
   PubMed Web of Science ®Google Scholar
• Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol. 2000; 27 4: 866–873.
   PubMed Web of Science ®Google Scholar
• Catalano MA, Carson DA, Slovin SF, Richman DD, Vaughan JH. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci USA. 1979; 76 11: 5825–5828.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Kojima N, Takeuchi F, Mizuochi T. Kinetic analysis of interaction of different types of rheumatoid factors with immobilized IgG using surface plasmon resonance. J Biochem (Tokyo). 2000; 128 6: 1009–1016.
   PubMed Web of Science ®Google Scholar
• Lee D, Schur P. Personal communication.
   Google Scholar
• Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer FE. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol. 1987; 126 2: 319–325.
   PubMed Web of Science ®Google Scholar
• Bertrand KA, Birmann BM, Chang ET, Spiegelman D, Aster JC, Zhang SM, Laden F. A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma. Blood. 2010; 116 18: 3547–3553.
   PubMed Web of Science ®Google Scholar
• Ferrell PB, Aitcheson CT, Pearson GR, Tan EM. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J Clin Invest. 1981; 67 3: 681–687.
   PubMed Web of Science ®Google Scholar
• Hazelton RA, Sculley TB, Pope JH. The prevalence of antibodies to an Epstein-Barr virus-induced polypeptide (EBNA-2) in the sera of rheumatoid arthritic families. Br J Rheumatol. 1987; 26 3: 193–196.
   PubMedGoogle Scholar
• Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, Roudier J, Roudier C. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: Accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003; 48 5: 1223–1228.
   PubMed Web of Science ®Google Scholar
• Saal JG, Krimmel M, Steidle M, Gerneth F, Wagner S, Fritz P, Koch S, Zacher J, Sell S, Einsele H, Müller CA. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum. 1999; 42 7: 1485–1496.
   PubMedGoogle Scholar
• Balandraud N, Guis S, Baptiste Meynard J, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57 5: 762–767.
   PubMed Web of Science ®Google Scholar
• Takei M, Mitamura K, Fujiwara S, Horie T, Ryu J, Osaka S, Yoshino S, Sawada S. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol. 1997; 9 5: 739–743.
   PubMed Web of Science ®Google Scholar
• Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43 6: 1218–1225.
   PubMedGoogle Scholar
• Bardwick PA, Bluestein HG, Zvaifler NJ, Depper JM, Seegmiller JE. Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells. Arthritis Rheum. 1980; 23 6: 626–632.
   PubMedGoogle Scholar
• Depper JM, Bluestein HG, Zvaifler NJ. Impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid arthritis is due to a T cell defect. J Immunol. 1981; 127 5: 1899–1902.
   PubMed Web of Science ®Google Scholar
• Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med. 1981; 305 21: 1238–1243.
   PubMed Web of Science ®Google Scholar
• Gaston JS, Rickinson AB, Epstein MA. Epstein-Barr virus-specific cytotoxic T cell responses in rheumatoid arthritis patients. Rheumatol Int. 1982; 2 4: 155–159.
   PubMed Web of Science ®Google Scholar
• Stierle HE, Brown KA, Perry JD, Holborow EJ. Increased responsiveness of rheumatoid B lymphocytes to stimulation by Epstein-Barr virus. Rheumatol Int. 1983; 3 1: 7–11.
   PubMed Web of Science ®Google Scholar
• Kahan A, Amor B, Menkes CJ. Different defects of T cell regulation of Epstein-Barr virus-induced B cell activation in rheumatoid arthritis. Arthritis Rheum. 1985; 28 9: 961–970.
   PubMedGoogle Scholar
• Toussirot E, Wendling D, Tiberghien P, Luka J, Roudier J. Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Ann Rheum Dis. 2000; 59 7: 533–538.
   PubMed Web of Science ®Google Scholar
• Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, Lim A, Even J, Semana G, Berthelot JM, Breathnach R, Bonneville M, Houssaint E. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med. 1996; 184 5: 1791–1800.
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Munger KL, Ascherio A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. Eur J Neurol. 2004; 11 12: 833–834.
   PubMed Web of Science ®Google Scholar
• Jorgensen KT, Wiik A, Pedersen M, Hedegaard CJ, Vestergaard BF, Gislefoss RE, Kvien TK, Wohlfahrt J, Bendtzen K, Frisch M. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: Case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis. 2008; 67 6: 860–866.
   PubMed Web of Science ®Google Scholar